KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Operating Leases (2019 - 2025)

NovoCure's Operating Leases history spans 7 years, with the latest figure at $41.6 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 108.54% year-over-year to $41.6 million; the TTM value through Dec 2025 reached $41.6 million, up 108.54%, while the annual FY2025 figure was $41.6 million, 108.54% up from the prior year.
  • Operating Leases for Q4 2025 was $41.6 million at NovoCure, down from $42.7 million in the prior quarter.
  • Across five years, Operating Leases topped out at $42.9 million in Q2 2025 and bottomed at $11.5 million in Q3 2021.
  • The 5-year median for Operating Leases is $20.2 million (2023), against an average of $22.8 million.
  • The largest annual shift saw Operating Leases dropped 27.17% in 2024 before it surged 108.54% in 2025.
  • A 5-year view of Operating Leases shows it stood at $13.0 million in 2021, then skyrocketed by 44.36% to $18.8 million in 2022, then soared by 46.15% to $27.4 million in 2023, then decreased by 27.17% to $20.0 million in 2024, then soared by 108.54% to $41.6 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Operating Leases are $41.6 million (Q4 2025), $42.7 million (Q3 2025), and $42.9 million (Q2 2025).